Amwell Q3 revenue of $49.0 million beats guidance; 2026 revenue outlook raised
Amwell reported third-quarter 2026 revenue of $49.0 million, down from $56.3 million a year earlier but above its prior guidance range. The company raised its 2026 revenue and adjusted EBITDA outlook, while its net loss and adjusted EBITDA loss were both wider than in the second quarter of 2026.
Key points
- Q3 2026 revenue was $49.0 million versus $56.3 million in Q3 2025, including $23.9 million of subscription revenue and $23.7 million of AMG visit revenue.
- Net loss was $11.0 million versus $31.9 million in Q3 2025 and $9.6 million in Q2 2026.
- Adjusted EBITDA was a loss of $3.6 million versus a $12.7 million loss in Q3 2025 and a $1.2 million loss in Q2 2026.
- 2026 revenue guidance was raised to $204 million to $206 million from $200 million to $205 million; Q4 2026 revenue is expected at $48 million to $50 million.
The filing
Written by AI on Nov 9, 2026, 10:08 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on November 03, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.